228 related articles for article (PubMed ID: 34222333)
1. Blocking K-Ras Interaction With the Plasma Membrane Is a Tractable Therapeutic Approach to Inhibit Oncogenic K-Ras Activity.
Henkels KM; Rehl KM; Cho KJ
Front Mol Biosci; 2021; 8():673096. PubMed ID: 34222333
[TBL] [Abstract][Full Text] [Related]
2. Chalcones bearing a 3,4,5-trimethoxyphenyl motif are capable of selectively inhibiting oncogenic K-Ras signaling.
Kovar SE; Fourman C; Kinstedt C; Williams B; Morris C; Cho KJ; Ketcha DM
Bioorg Med Chem Lett; 2020 Jun; 30(11):127144. PubMed ID: 32276831
[TBL] [Abstract][Full Text] [Related]
3. Avicin G is a potent sphingomyelinase inhibitor and blocks oncogenic K- and H-Ras signaling.
Garrido CM; Henkels KM; Rehl KM; Liang H; Zhou Y; Gutterman JU; Cho KJ
Sci Rep; 2020 Jun; 10(1):9120. PubMed ID: 32499517
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of K-Ras plasma membrane localization.
Cho KJ; van der Hoeven D; Hancock JF
Enzymes; 2013; 33 Pt A():249-65. PubMed ID: 25033808
[TBL] [Abstract][Full Text] [Related]
5. A new ferrocene derivative blocks KRAS localization and function by oxidative modification at His95.
Rehl KM; Selvakumar J; Hoang D; Arumugam K; Gorfe AA; Cho KJ
bioRxiv; 2023 Mar; ():. PubMed ID: 37034642
[TBL] [Abstract][Full Text] [Related]
6. Sphingomyelin Metabolism Is a Regulator of K-Ras Function.
van der Hoeven D; Cho KJ; Zhou Y; Ma X; Chen W; Naji A; Montufar-Solis D; Zuo Y; Kovar SE; Levental KR; Frost JA; van der Hoeven R; Hancock JF
Mol Cell Biol; 2018 Feb; 38(3):. PubMed ID: 29158292
[TBL] [Abstract][Full Text] [Related]
7. A new ferrocene derivative blocks K-Ras localization and function by oxidative modification at His95.
Rehl KM; Selvakumar J; Pitsch RL; Hoang D; Arumugam K; Harshman SW; Gorfe AA; Cho KJ
Life Sci Alliance; 2023 Nov; 6(11):. PubMed ID: 37666666
[TBL] [Abstract][Full Text] [Related]
8. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology.
Van Sciver RE; Lee MP; Lee CD; Lafever AC; Svyatova E; Kanda K; Colliver AL; Siewertsz van Reesema LL; Tang-Tan AM; Zheleva V; Bwayi MN; Bian M; Schmidt RL; Matrisian LM; Petersen GM; Tang AH
Cancers (Basel); 2018 May; 10(5):. PubMed ID: 29757973
[TBL] [Abstract][Full Text] [Related]
9. An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth.
Tan L; Cho KJ; Neupane P; Capon RJ; Hancock JF
J Biol Chem; 2018 Aug; 293(35):13696-13706. PubMed ID: 29970615
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors.
Ye N; Xu Q; Li W; Wang P; Zhou J
Curr Top Med Chem; 2019; 19(23):2114-2127. PubMed ID: 31475899
[TBL] [Abstract][Full Text] [Related]
11. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
12. Staurosporines disrupt phosphatidylserine trafficking and mislocalize Ras proteins.
Cho KJ; Park JH; Piggott AM; Salim AA; Gorfe AA; Parton RG; Capon RJ; Lacey E; Hancock JF
J Biol Chem; 2012 Dec; 287(52):43573-84. PubMed ID: 23124205
[TBL] [Abstract][Full Text] [Related]
13. Conformation-specific inhibitors of activated Ras GTPases reveal limited Ras dependency of patient-derived cancer organoids.
Wiechmann S; Maisonneuve P; Grebbin BM; Hoffmeister M; Kaulich M; Clevers H; Rajalingam K; Kurinov I; Farin HF; Sicheri F; Ernst A
J Biol Chem; 2020 Apr; 295(14):4526-4540. PubMed ID: 32086379
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
Nussinov R; Tsai CJ; Jang H
Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
[TBL] [Abstract][Full Text] [Related]
15. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.
Köthe S; Müller JP; Böhmer SA; Tschongov T; Fricke M; Koch S; Thiede C; Requardt RP; Rubio I; Böhmer FD
J Cell Sci; 2013 Oct; 126(Pt 20):4746-55. PubMed ID: 23943874
[TBL] [Abstract][Full Text] [Related]
16. Depletion of phosphatidylinositol 4-phosphate at the Golgi translocates K-Ras to mitochondria.
Miller TE; Henkels KM; Huddleston M; Salisbury R; Hussain SM; Sasaki AT; Cho KJ
J Cell Sci; 2019 Aug; 132(16):. PubMed ID: 31331963
[TBL] [Abstract][Full Text] [Related]
17. Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase.
Lee J; Choi KJ; Lim MJ; Hong F; Choi TG; Tak E; Lee S; Kim YJ; Chang SG; Cho JM; Ha J; Kim SS
Cell Res; 2010 Aug; 20(8):919-34. PubMed ID: 20603646
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of K-Ras4B-plasma membrane association with a membrane microdomain-targeting peptide.
Li FY; Zhang ZF; Voss S; Wu YW; Zhao YF; Li YM; Chen YX
Chem Sci; 2019 Dec; 11(3):826-832. PubMed ID: 34123058
[TBL] [Abstract][Full Text] [Related]
19. Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation.
Nussinov R; Tsai CJ; Muratcioglu S; Jang H; Gursoy A; Keskin O
Expert Rev Proteomics; 2015; 12(6):669-82. PubMed ID: 26496174
[TBL] [Abstract][Full Text] [Related]
20. CaM interaction and Ser181 phosphorylation as new K-Ras signaling modulators.
Alvarez-Moya B; Barceló C; Tebar F; Jaumot M; Agell N
Small GTPases; 2011 Mar; 2(2):99-103. PubMed ID: 21776410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
